Page 8 - Johnson & Johnson

J&J to add prices to TV ads making drug prices transparent for consumers

CHICAGO (Reuters) - Johnson & Johnson said on Thursday it will start adding the price of its medicines to television commercials by next month, becoming the first drugmaker to heed a call by U.S. President Donald Trump for price transparency of drugs advertised directly to consumers on TV.

$120 mn: Cost Johnson & Johnson will pay to settle hip-implant claims in US

(Reuters) - Johnson & Johnson and its DePuy Orthopaedics unit have agreed to pay $120 million to resolve deceptive marketing claims by several U.S. states over the company's metal-on-metal hip implants.

SC accepts govt response on compensation for J&J hip implant victims

Panel had recommended compensation of up to Rs 1.22 crore for victims

Take action against J&J over faulty hip implants: 10 MPs write to Nadda

Ten MPs, seven of them belonging to BJP ally Shiv Sena, have written to Union Health Minister J P Nadda to take "appropriate action" against global healthcare major Johnson and Johnson (J&J) and "ensure justice for all sufferers" of faulty ASR hip implants. Union Minister of State for Health and Family Welfare Anupriya Patel, who belongs to BJP ally Apna Dal(Sonelal), is among the 10 MPs to have written to Nadda. "Most recently, the company (J&J) seems to be going against the government's directions and denying its liability in compensating patients," Chandrakant Khaire, Shiv Sena MP from Aurangabad in Maharashtra, wrote in a letter dated January 7. "I call upon you 'sir' (Nadda) to independently identify all patients who have received the faulty ASR implants in India; and take appropriate action/s against the company to ensure that justice is met to all the sufferers of these faulty ASR (hip) implants (sic)," Khaire added. In December last year, J&J had approached the ...

India orders Johnson & Johnson to stop using raw material for Baby Powder

US company asked to stop using the 'huge quantities' of raw materials stocked in its plants in northern and western India.

J&J says talc powder in India safe, drug regulators visited plants

Regulators in India launch an investigation into Johnson & Johnson's Baby Powder following report that the firm knew for decades that cancer-causing asbestos lurked in the product.

Drug regulator to test samples of J&J baby powder over asbestos claims

NEW DELHI (Reuters) - India's drug regulator will on Wednesday seize samples of Johnson & Johnson's baby powder for testing, local media said, following a Reuters report that the company knew for decades that cancer-causing asbestos lurked in the product.

'Science. not sensationalism', J&J moves to weather the storm on powder row

J&J shares fell nearly 3% Monday. That drop was on top of the 10% plunge that wiped out about $40 billion of the company's market capitalization following the Reuters report

J&J plans $5 bn share buyback after report wipes out $50 bn in market value

(Reuters) - Johnson & Johnson said on Monday it plans to buy back up to $5 billion of its stock, after a Reuters report on Friday that the company knew for decades that its Baby Powder contained cancer-causing asbestos wiped about $40 billion from its market value.

J&J shares extend losses on reports of asbestos in baby powder

(Reuters) - Shares of Johnson & Johnson slipped another 2 percent on Monday, extending losses following Friday's Reuters report that the healthcare conglomerate knew for decades that cancer-causing asbestos lurked in its Baby Powder.

Johnson & Johnson's intraday plunge over 'asbestos report' wipes out $45 bn

The last time shares of Johnson & Johnsons came under this much pressure was due to asbestos concerns back in February

Johnson & Johnson is willing to pay $400 million-plus in hip-device cases

Company seeks end to Pinnacle hip suits before January trial

J&J implant case: Govt confident of making MNC compensate affected patients

The central government expects to make a legally convincing case on making Johnson & Johnson compensate people for its faultily made hip implants.The multinational company has petitioned the high court at Delhi to argue it is not liable to pay. However, a public interest suit to compel it is pending before the Supreme Court (SC). "Our Drugs and Cosmetics Act did not have a provision for compensation. J&J's main contention is that there is no provision under current law to compensate patients. We have already taken steps to plug the gap. Globally, J&J is paying affected patients, mostly through litigation or out-of-court settlements. There is no reason why they will not compensate the Indian patients," say senior health ministry sources.The implants manufactured by J&J's wholly-owned subsidiary, DePuy International, were faulty, and several instances of revision surgeries were reported in India and across the globe.The laws in several other countrues, said one official

Faulty hip implants case: J&J willing to pay over $400 mn to US consumers

J&J officials have agreed to pay an average of about $125,000 per case to resolve about a third of the suits pending against the company over Pinnacle hips

277 surgeries performed due to faulty J&J hip implants: Minister

A total of 277 revision surgeries have been performed due to the faulty ASR hip implants manufactured by DePuy International Ltd, a subsidiary of Johnson and Johnson, Minister of State for Health Ashwini Choubey told the Rajya Sabha Tuesday. The minister was replying to a question on whether faulty hip implants had resulted in deaths and disability of several patients. "As per the information available with the Central Drugs Standard Control Organisation (CDSCO), 277 revision surgeries were undertaken because of disability due to faulty Articular Surface Replacement (ASR) hip implants manufactured by M/s DePuy International Limited, UK, (now M/s Johnson & Johnson Pvt Ltd)," Choubey said in his reply. He said the government had set up a panel to examine issues relating to the faulty hip implants. The committee, after a detailed examination of the issue, submitted its report to the government, which accepted the recommendations with some modifications. Based on the accepted ...

Setback for Johnson & Johnson's HC plea in hip implants compensation case

Govt had asked J&J to pay compensation to faulty hip implant patients

J&J faulty hip implant row: Noose tightens around medical devices importers

DTAB passed a proposal to include a provision in the MDR for cancellation and suspension of import licence of the medical devices in case of noncompliance with the regulatory provisions

Johnson & Johnson loses cancer drug patent, Indian firms eye US market

Dr Reddy's, Glenmark, Wockhardt have lined up alternatives for Zytiga

From head to toe, J&J is trying to reconquer the baby-care market

After missing out on major shifts in consumer tastes and watching sales stall, the company has remade its baby line. Catching up won't be easy

Patients seek clarity on proposed compensation in J&J faulty implants case

Amid reports that the victims of Johnson & Johnson's faulty hip implants are likely to get as much as Rs 1.2 crore each in compensation, some patients have sought official clarification about the proposed compensation and the basis of deciding on a formula in the absence of any consultation with them. In a letter to Union Health Minister J P Nadda, more than 30 patients have reiterated their concerns regarding the lack of transparency and patient consultation in the process to decide compensation, including lack of information being made available regarding deliberations of the Arya Committee and the formulation of compensation norms. "We are unclear about the basis of deciding on a formula in the absence of any consultation with patients to understand the range of our suffering because of the hip implants, the aggravation of pain and misery caused by unjustifiably delayed medical attention and other negative impacts on our lives. "We question why we have to rely on media reports .